- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06270901
Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolism in Participants With Increased Cardiometabolic Risk (LeguPlan_1)
April 12, 2024 updated by: Prof. Dr. Sarah Egert, University of Bonn
Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolic Response in Women and Men at Increased Risk of Cardiovascular and Neurodegenerative Diseases
The aim of the study is to investigate the postprandial effects of legume-enriched meals compared to Western Diet meals on postprandial metabolism.
In this context, older adults with increased risk for cardiometabolic diseases consume 4 mixed meals with 36 g or 62 g of protein either designed according to the Planetary Health Diet with legumes as primary protein source or the Western Diet with animal foods as primary protein source, in a randomized order.
In a postprandial observation period of 6 hours, parameters of lipid metabolism, glucose and insulin metabolism, amino acid profile, as well as markers of inflammation and vascular function are analysed.
Furthermore, neuropsychological parameters and satiety-associated hormones are investigated.
Study Overview
Status
Recruiting
Conditions
Detailed Description
In a randomized crossover design, 30 older men and women with increased risk for cardiometabolic diseases consume 4 mixed meals, which differ in dietary pattern, protein source and protein quantity.
Two meals are designed according to the Planetary Health Diet with legumes as primary protein source whereas the other two meals are designed according to the Western Diet with animal food as primary protein source.
Two meals are designed as high protein meals (62 g of protein) and two meals are designed as low protein meals (36 g of Protein).
Therefore, participants consume 4 different test meals, a Low and a High Protein Western Diet Meal and a Low and a High Protein Planetary Health Diet Meal in a randomized order.
During a postprandial observation period of 6 hours, parameters of lipid metabolism (e.g., plasma triglycerides), glucose metabolism (e.g., plasma glucose, serum insulin), as well as markers of inflammation (e.g., IL-6) and vascular function (e.g., pulse wave velocity) are analysed.
Furthermore, amino acid profile, neuropsychologic parameters (e.g., appetite) and satiety-associated hormones (e.g., Ghrelin) are investigated.
Each intervention will be separated by a washout period of approximately 14 days.
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North-Rhine Westphalia
-
Bonn, North-Rhine Westphalia, Germany, 53115
- Recruiting
- University of Bonn, Institute of Nutritional and Food Sciences, Nutrition Physiology
-
Contact:
- Sarah Egert, Prof. Dr.
- Phone Number: + 49 (0) 228 / 73 59
- Email: s.egert@uni-bonn.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- written informed consent
- Non-smoking
- BMI: 27 - 34,9 kg/m2
- Waist circumference (women ≥ 80 cm, men ≥ 94 cm)
- Systolic blood pressure: ≥ 120 mmHg, diastolic blood pressure: ≥ 80 mmHg
- At least one of the following criteria
- Fasting triglycerides in serum: ≥ 150 mg/dL
- Fasting HDL-Cholesterol in serum: women < 50 mg/dl, men < 40 mg/dL
- Fasting C-reactive protein in serum: ≥ 2 mg/L
- Fasting glucose in plasma: ≥ 100 mg/dL
Exclusion Criteria:
- food intolerances and allergies (especially to legumes)
- Smoking
- malabsorption syndromes
- thyroid diseases
- impaired renal function
- chronic liver disease
- heart failure
- myocardial infarction
- insulin-dependent diabetes mellitus
- chronic inflammatory diseases
- tumors
- anemia
- immunosuppression
- intake of supplements (e.g., fish oil)
- Participation in another study
- other exclusion criteria at the discretion of the physician/ investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High Protein Planetary Health Diet
High Protein Planetary Health Diet Meal: This meal contains 62 g of protein primarily from plant origin (particularly legumes)
|
Planetary Health Diet Meal with 62 g of protein primarily from plant origin
|
Experimental: Low Protein Planetary Health Diet
Low Protein Planetary Health Diet Meal: This meal contains 36 g of protein from primarily plant origin (particularly legumes)
|
Planetary Health Diet Meal with 36 g of protein primarily from plant origin
|
Experimental: High Protein Western Diet
High Protein Western Diet Meal: This meal contains 62 g of protein primarily form animal origin
|
Western Diet Meal with 62 g of protein primarily from animal origin
|
Experimental: Low Protein Western Diet
Low Protein Western Diet Meal: This meal contains 36 g of protein primarily from animal origin
|
Western Diet Meal with 36 g of protein primarily from animal origin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parameters of lipid metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Triglycerides (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Parameters of lipid metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Total cholesterol (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Parameters of lipid metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
LDL cholesterol (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Parameters of lipid metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
HDL cholesterol (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Parameters of lipid metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Free fatty acids (mmol/L)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Parameters of glucose metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
Glucose (mg/dL)
|
Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
Parameters of glucose metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
Insulin (nmol/L)
|
Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
Parameters of glucose metabolism in blood
Time Frame: Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
cPeptide (pg/mL)
|
Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 6 hours)
|
Parameters of glucose metabolism in blood
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
GLP-1 (pg/mL)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Parameters of glucose metabolism in blood
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Glucagon (pg/mL)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Blood amino acid profile
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Amino acid profile in blood (nmol/mL)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Blood urea
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Urea in blood (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Uric acid in blood
Time Frame: Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Uric acid in blood (mg/dL)
|
Postprandial period of 6 hours (T=0, 1, 2, 3, 4, 6 hours)
|
Parameters of hunger and satiety in blood
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
e.g. Ghrelin (pg/mL)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Parameters of endothelial function in blood
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
e.g. ADMA (µmo/L)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Parameters of inflammation in blood
Time Frame: Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
e.g. IL-6 (pg/mL)
|
Postprandial period of 6 hours (T= 0, 1, 2, 3, 4, 6 hours)
|
Endothelial function
Time Frame: Postprandial period of 6 hours (T=0, 2, 4, 6 hours)
|
e.g. pulse wave velocity (m/s)
|
Postprandial period of 6 hours (T=0, 2, 4, 6 hours)
|
Neuropsychological parameters
Time Frame: Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours)
|
Assessment of hunger and satiety via a visual analogue scale (e.g.
0 = not hungry at all to 10 = very hungry)
|
Postprandial period of 6 hours (T=0, 0.5, 1, 1.5, 2, 3, 4, 5, 6 hours)
|
Neuropsychological parameters
Time Frame: Postprandial period of 4.5 hours (T= 0, 1.5, 3, 4.5 hours)
|
Assessment of attention via questionnaire (paper pencil test, e.g. higher amount of marked target items = higher attention, maximum points 640 = every target items marked correctly, minimum points: 0 = no target items marked or only wrong items marked)
|
Postprandial period of 4.5 hours (T= 0, 1.5, 3, 4.5 hours)
|
Neuropsychological parameters
Time Frame: Postprandial period of 6 hours (T=0.5, 3, 6 hours)
|
Assessment of memory via questionnaire (paper pencil, e.g. higher reproduction of memorised visual and verbal information = better memory; visual part: maximum points: 31 = all visual information memorised, minimum points: 0 = no visual information memorised; verbal part: maximum points: 24 = all verbal information memorised, minimum points: 0 = no verbal information memorised)
|
Postprandial period of 6 hours (T=0.5, 3, 6 hours)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 1, 2024
Primary Completion (Estimated)
July 30, 2024
Study Completion (Estimated)
July 30, 2024
Study Registration Dates
First Submitted
February 2, 2024
First Submitted That Met QC Criteria
February 13, 2024
First Posted (Actual)
February 21, 2024
Study Record Updates
Last Update Posted (Estimated)
April 15, 2024
Last Update Submitted That Met QC Criteria
April 12, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BMEL: 2822EPS008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on High Protein Planetary Health Diet
-
Universidad de SonoraNot yet recruitingObesity | OverweightMexico
-
Indonesia UniversityNot yet recruitingOverweight and Obesity | Health Behavior | Eating Behavior | Calorie Overload
-
Stanford UniversityCompletedDiet, Food and NutritionUnited States
-
Wageningen UniversityTop Institute Food and NutritionCompletedIdentify New Biomarkers in Blood or Urine After Consumption of Meat Protein, Dairy Protein and Grain Protein in Healthy Subjects.Netherlands
-
Rio de Janeiro State UniversityRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed
-
Erik Ramirez LopezCompletedWeight Loss | Body CompositionMexico
-
University of TennesseeUnknownInflammation | ObesityUnited States
-
Regional Hospital HolstebroCompleted
-
Chang Gung Memorial HospitalCompletedIschemic Stroke | Diet, Healthy | Muscle LossTaiwan
-
University of Alabama at BirminghamCompletedObesity | Diet Modification | Diabetes Type 2United States